515 related articles for article (PubMed ID: 22005056)
21. First report of New Delhi metallo-β-lactamase-1-producing strains in Slovakia.
Kulkova N; Babalova M; Sokolova J; Krcmery V
Microb Drug Resist; 2015 Feb; 21(1):117-20. PubMed ID: 25343711
[TBL] [Abstract][Full Text] [Related]
22. Development of Peptides that Inhibit Aminoglycoside-Modifying Enzymes and β-Lactamases for Control of Resistant Bacteria.
Costa BO; Cardoso MH; Franco OL
Curr Protein Pept Sci; 2020; 21(10):1011-1026. PubMed ID: 32933457
[TBL] [Abstract][Full Text] [Related]
23. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta-lactamases and metallo-beta-lactamases on the treatment of resistant Gram-negative pathogens.
Helfand MS; Bonomo RA
Curr Opin Pharmacol; 2005 Oct; 5(5):452-8. PubMed ID: 16084766
[TBL] [Abstract][Full Text] [Related]
24. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.
Alm RA; Johnstone MR; Lahiri SD
J Antimicrob Chemother; 2015 May; 70(5):1420-8. PubMed ID: 25634992
[TBL] [Abstract][Full Text] [Related]
25. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria.
Walsh TR
Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():2-9. PubMed ID: 16209700
[TBL] [Abstract][Full Text] [Related]
26. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.
Durand-Réville TF; Guler S; Comita-Prevoir J; Chen B; Bifulco N; Huynh H; Lahiri S; Shapiro AB; McLeod SM; Carter NM; Moussa SH; Velez-Vega C; Olivier NB; McLaughlin R; Gao N; Thresher J; Palmer T; Andrews B; Giacobbe RA; Newman JV; Ehmann DE; de Jonge B; O'Donnell J; Mueller JP; Tommasi RA; Miller AA
Nat Microbiol; 2017 Jun; 2():17104. PubMed ID: 28665414
[TBL] [Abstract][Full Text] [Related]
27. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
Karaiskos I; Galani I; Souli M; Giamarellou H
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
[TBL] [Abstract][Full Text] [Related]
28. [Infectious diseases caused by carbapenemase-producing Enterobacteriaceae--a particular challenge for antibacterial therapy].
Stock I
Med Monatsschr Pharm; 2014 May; 37(5):162-72; quiz 173-4. PubMed ID: 24908928
[TBL] [Abstract][Full Text] [Related]
29. Structural studies on New Delhi Metallo-β-lactamase (NDM-2) suggest old β-lactam, penicillin to be better antibiotic for NDM-2-harbouring Acinetobacter baumanni.
Tiwari V; Moganty RR
J Biomol Struct Dyn; 2013; 31(6):591-601. PubMed ID: 22888760
[TBL] [Abstract][Full Text] [Related]
30. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
[TBL] [Abstract][Full Text] [Related]
32. Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.
Mojica MF; Papp-Wallace KM; Taracila MA; Barnes MD; Rutter JD; Jacobs MR; LiPuma JJ; Walsh TJ; Vila AJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784669
[No Abstract] [Full Text] [Related]
33. Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance.
Johnson AP; Woodford N
J Med Microbiol; 2013 Apr; 62(Pt 4):499-513. PubMed ID: 23329317
[TBL] [Abstract][Full Text] [Related]
34. New β-lactam antibiotics and β-lactamase inhibitors.
Bush K; Macielag MJ
Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
[TBL] [Abstract][Full Text] [Related]
35. β-Lactamases and β-Lactamase Inhibitors in the 21st Century.
Tooke CL; Hinchliffe P; Bragginton EC; Colenso CK; Hirvonen VHA; Takebayashi Y; Spencer J
J Mol Biol; 2019 Aug; 431(18):3472-3500. PubMed ID: 30959050
[TBL] [Abstract][Full Text] [Related]
36. NDM-1 (New Delhi metallo beta lactamase-1) producing Gram-negative bacilli: emergence & clinical implications.
Fomda BA; Khan A; Zahoor D
Indian J Med Res; 2014 Nov; 140(5):672-8. PubMed ID: 25579151
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and molecular characterisation of New Delhi metallo-β-lactamases NDM-1, NDM-5, NDM-6 and NDM-7 in multidrug-resistant Enterobacteriaceae from India.
Rahman M; Shukla SK; Prasad KN; Ovejero CM; Pati BK; Tripathi A; Singh A; Srivastava AK; Gonzalez-Zorn B
Int J Antimicrob Agents; 2014 Jul; 44(1):30-7. PubMed ID: 24831713
[TBL] [Abstract][Full Text] [Related]
38. Extended-spectrum beta-lactamases: a brief clinical update.
Malloy AM; Campos JM
Pediatr Infect Dis J; 2011 Dec; 30(12):1092-3. PubMed ID: 22105419
[No Abstract] [Full Text] [Related]
39. The spread and acquisition of NDM-1: a multifactorial problem.
Wailan AM; Paterson DL
Expert Rev Anti Infect Ther; 2014 Jan; 12(1):91-115. PubMed ID: 24308710
[TBL] [Abstract][Full Text] [Related]
40. In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms.
Sy SK; Beaudoin ME; Zhuang L; Löblein KI; Lux C; Kissel M; Tremmel R; Frank C; Strasser S; Heuberger JA; Mulder MB; Schuck VJ; Derendorf H
J Antimicrob Chemother; 2016 Jul; 71(7):1866-80. PubMed ID: 27107096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
